KalVista Pharmaceuticals (KALV) Earnings Date, Estimates & Call Transcripts $12.34 -0.53 (-4.12%) (As of 09/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateDec. 5EstimatedActual EPS (Sep. 5) -$0.87 Beat By $0.04 Consensus EPS (Sep. 5) -$0.91 Get KalVista Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for KALV and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueKALV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KALV Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. KalVista Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($1.14)($0.73)($0.94)Q2 20243($0.94)($0.66)($0.79)Q3 20243($0.98)($0.69)($0.82)Q4 20243($1.03)($0.55)($0.78)FY 202411($4.09)($2.63)($3.33)Q1 20252($0.90)($0.72)($0.81)Q2 20252($0.91)($0.71)($0.81)Q3 20252($0.89)($0.71)($0.80)Q4 20252($0.84)($0.70)($0.77)FY 20258($3.54)($2.84)($3.19)KALV Earnings Date and InformationKalVista Pharmaceuticals last released its quarterly earnings results on September 5th, 2024. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04. KalVista Pharmaceuticals has generated ($3.40) earnings per share over the last year (($3.40) diluted earnings per share). Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($1.61) per share. KalVista Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 5th, 2024 based off prior year's report dates.Read More KalVista Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 12/5/2024(Estimated)------- 9/5/2024Q1 2025($0.91)($0.87)+$0.04($0.87)--7/11/2024Q4 2024($0.73)($1.02)($0.29)($1.02)-- 3/11/2024Q3 2024($0.75)($0.84)($0.09)($0.84)-- 12/7/2023Q4 2023($0.76)($0.80)($0.04)($0.80)-- 9/7/2023Q3 2023($0.86)($0.74)+$0.12($0.74)-- 7/7/2023Q2 2023($0.87)($0.77)+$0.10($0.77)-- Get the Latest News and Ratings for KALV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 3/9/2023Q3 2023($0.97)($0.75)+$0.22($0.75)-- 12/8/2022Q2 2023($1.04)($0.90)+$0.14($0.90)-- 9/8/2022Q1 2023($1.02)($0.94)+$0.08($0.94)-- 7/7/2022Q4 2022($1.06)($0.98)+$0.08($0.98)-- 3/10/2022Q3 2022($0.91)($0.92)($0.01)($0.92)-- 12/9/2021Q2($0.7910)($0.80)($0.0090)($0.80)-- 9/8/2021Q3 2021($0.71)($0.66)+$0.05($0.66)-- 7/12/2021Q2 2021($0.56)($0.65)($0.09)($0.65)--3/11/2021Q1 2021($0.60)($0.56)+$0.04($0.56)--12/9/2020Q4 2020($0.67)($0.58)+$0.09($0.58)--9/14/2020Q3 2020($0.60)($0.61)($0.01)($0.61)--7/1/2020Q2 2020($0.65)($0.37)+$0.28($0.37)$2.05 million$3.82 million3/10/2020Q1 2020($0.26)($0.52)($0.26)($0.52)$3.30 million$1.58 million12/3/2019Q2 2020($0.55)($0.33)+$0.22($0.33)$3.23 million$3.92 million9/9/2019Q1($0.62)($0.42)+$0.20($0.42)$3.24 million$3.37 million KalVista Pharmaceuticals Earnings - Frequently Asked Questions When is KalVista Pharmaceuticals's earnings date? KalVista Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 5th, 2024 based off last year's report dates. Learn more on KALV's earnings history. Did KalVista Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, KalVista Pharmaceuticals (NASDAQ:KALV) reported ($0.87) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.91) by $0.04. Learn more on analysts' earnings estimate vs. KALV's actual earnings. How much profit does KalVista Pharmaceuticals generate each year? KalVista Pharmaceuticals (NASDAQ:KALV) has a recorded net income of -$126.64 million. KALV has generated -$3.40 earnings per share over the last four quarters. What is KalVista Pharmaceuticals's EPS forecast for next year? KalVista Pharmaceuticals's earnings are expected to grow from ($3.57) per share to ($1.61) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ABUS Earnings Results ALIM Earnings Results BCRX Earnings Results VERA Earnings Results MIRM Earnings Results HRMY Earnings Results GLPG Earnings Results ZLAB Earnings Results KNSA Earnings Results EWTX Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:KALV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
